智通财经 · Sep 30 3:11
译 CRISPR / Vertex 的镰状细胞基因疗法符合欧洲加速审查的条件 The European Medicines Agency has granted Priority Medicines (PRIME) designation to CTX001, an autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of severe sickle cell disease (SCD) ... The drug candidate is in two Phase 1/2 trials designed to assess the safety and efficacy of a single dose of CTX001 in patients with transfusion-dependent beta thalassemia and severe sickle cell disease.
SeekingAlpha · Sep 22 9:54
Moderna 与 Vertex、Chiesi 达成总计超 9 亿美元合作 亿欧大健康 9 月 18 日获悉，近日 Moderna 陆续与 Vertex 和 Chiesi Farmaceutici 达成累计 1 亿美元的研发协议 ... 其中 Vertex（专注治疗囊性纤维化的药企）将向 Moderna 支付 7500 万美元，并承诺高达 3.8 亿美元的里程碑付款 ... 根据协议内容，Moderna 将发现并优化用于治疗囊性纤维化（CF）的脂质纳米颗粒（LNP），Vertex 旨在使用 LNP 对肺细胞进行基因编辑治疗，从而实现功能性囊性纤维化跨膜电导调节剂（CFTR）蛋白的表达。
亿欧 · Sep 18 7:58
译 Moderna 与 Vertex Pharma 扩大囊性纤维化伙伴关系 Moderna（NASDAQ：MRNA）与 Vertex Pharmaceuticals（NASDAQ：VRTX）签署了一项研究合作和许可协议，旨在发现和开发脂质纳米粒（LNP）和 mRNA，以提供用于囊性纤维化（CF）的基因编辑疗法。 ..为期三年的合作伙伴关系的最初重点将是发现和优化新型 LNP 和 mRNA，这些 LNP 和 mRNA 可以将基因编辑疗法传递给肺中的细胞，从而可以产生囊性纤维化跨膜电导调节剂（CFTR）蛋白。根据该协议的条款，Moderna 将进行研究，以发现和优化新型 LNP，以将基因编辑疗法传递至肺细胞以治疗 CF。
SeekingAlpha · Sep 17 4:48
译 EC 验证 Vertex 的营销应用程序可扩展使用 Kaftiro + Ivacaftor The European Medicines Agency (EMA) has validated Vertex Pharmaceuticals' (NASDAQ:VRTX) Type II Variation Marketing Authorization Application for the expanded indication of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat Cystic Fibrosis (CF) in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene ... The application will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP), which will issue an opinion to the European Commission (EC) regarding the potential approval for these patients ... Vertex is a compelling investment case for medium-term players to capture fantastic returns over the next multiple periods on a background of strong fundamentals, writes Zach Bristow in his article "Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players," at Seeking Alpha.
SeekingAlpha · Sep 14 5:23
译 Vertex 制药公司报告儿童重磅 CF 药物在儿童中的 3 期阳性结果 The company announced Thursday that a phase 3 trial of the drug, in which it was administered to 6- to 11-year-old patients, met both its primary endpoint (for safety and tolerability) and several secondary endpoints ... The next stage, said Vertex, is for the company to file a supplemental New Drug Application (NDA) for patients in that age group, which it will do in the fourth quarter ... "Our aim is to extend eligibility to all patients who may benefit from this transformative medicine, and the positive results from the study in children ages 6 through 11 years old allows us to take another step forward toward this goal," said CEO Carmen Bozic.
motley fool · Sep 11 3:32
译 Vertex 将在下个季度提交美国专利申请以扩大 Trikafta 的用途 Supplemental marketing application next quarter seeking approval of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children ages 6 through 11 years old with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation ... The FDA approved the triple combo regimen in October 2019 for CF patients at least 12 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
SeekingAlpha · Sep 10 9:26
译 Vertex Ventures China 募集资金 4.38 亿美元 PremiumVertex Ventures China, a part of Singapore state investor Temasek Holdings-backed Vertex Ventures, has fully closed its latest RMB-denominated fund at 3 billion yuan ($438 million), it announced in a WeChat post on September 7.
dealstreetasia · Sep 9 8:00
译 Do Ventures 为越南初创公司启动了 5000 万美元的基金，由 Naver，Vertex 和其他著名的 LP 支持 New investment firm Do Ventures announced today the first closing of its fund for Vietnamese startups, which is backed by several of Asia’s most notable institutional investors ... Called Do Ventures Fund I, the investment vehicle has hit more than half of its $50 million target, with limited partners including Korean internet giant Naver ... Do Ventures was founded by general partners Nguyen Manh Dung, former CEO of CyberAgent Ventures Vietnam and Thailand, and Vy Hoang Uyen Le, previously a general partner at ESP Capital.
TechCrunch · Sep 8 12:09
译 是 Vertex Pharmaceuticals 股票买入吗？ If you're thinking about adding some new stocks to your portfolio, here's why Vertex Pharmaceuticals ought to be one of them ... To illustrate the extent of the returns Vertex has generated for investors over the years, let's imagine you invested $5,000 in the company shortly after its stock split in 2000 ... Investors eagerly awaited Vertex Pharmaceuticals' second-quarter earnings release on July 30 to see whether the coronavirus pandemic had had any substantial effect on the company's top and bottom lines.
motley fool · Sep 7 7:30
译 FDA 接受了 Vertex 的三项补充申请，以扩大 CF 药物的用途 The FDA has accepted for review three supplemental marketing applications from Vertex Pharmaceuticals (NASDAQ:VRTX) seeking expanded labels for cystic fibrosis (CF) meds TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO (tezacaftor/ivacaftor and ivacaftor) and KALYDECO (ivacaftor) to include additional rare CFTR mutations ... The filings may also allow certain CF patients who are currently eligible for KALYDECO to become eligible for SYMDEKO or TRIKAFTA and certain people currently eligible for SYMDEKO may become eligible for TRIKAFTA.
SeekingAlpha · Sep 1 9:22
译 鉴于其诱人的财务前景，Vertex Pharmaceuticals Incorporated（NASDAQ：VRTX）的市场是否会出错？ A Side By Side comparison of Vertex Pharmaceuticals' Earnings Growth And 28% ROETo begin with, Vertex Pharmaceuticals has a pretty high ROE which is interesting ... Story continuesWe then compared Vertex Pharmaceuticals' net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 27% in the same period ... Is Vertex Pharmaceuticals Using Its Retained Earnings Effectively?Given that Vertex Pharmaceuticals doesn't pay any dividend to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.
Yahoo Finance · Sep 1 3:58